Related Experiment Videos
Mdr1 limits CYP3A metabolism in vivo
L B Lan1, J T Dalton, E G Schuetz
1Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
Molecular Pharmacology
|September 22, 2000
Summary
P-glycoprotein (Pgp) significantly impacts CYP3A drug metabolism by limiting substrate availability. Studies show Pgp deficiency increases erythromycin metabolism, highlighting its role in drug clearance.
Area of Science:
- Pharmacology
- Drug Metabolism
- Biochemistry
Background:
- CYP3A enzymes are crucial for metabolizing many drugs.
- P-glycoprotein (Pgp) is a major drug efflux transporter.
- The interplay between Pgp and CYP3A-mediated metabolism is not fully understood.
Purpose of the Study:
- To investigate the influence of P-glycoprotein (Pgp) on CYP3A-mediated metabolism.
- To determine if Pgp affects the hepatic metabolism of erythromycin, a CYP3A substrate.
Main Methods:
- Utilized the erythromycin breath test in mdr1-deficient and proficient mice.
- Measured hepatic CYP3A activity using [(14)C]N-methyl erythromycin and (14)CO(2) breath analysis.
- Assessed CYP3A levels and N-demethylase activity in liver microsomes.
Main Results:
- Erythromycin metabolism measured by breath test (14CO2) was significantly higher in Pgp-deficient mice (mdr1a/1b-/- and mdr1a-/-) compared to controls.
- This increased metabolism correlated with Pgp expression, not with direct CYP3A activity measurements in liver microsomes.
- Mice lacking Pgp showed 1.5- to 1.9-fold higher (14)CO(2) AUC and 2-fold higher CER(max).
Conclusions:
- P-glycoprotein (Pgp) plays a critical role in determining the extent of CYP3A-mediated drug metabolism.
- Pgp limits intracellular substrate availability, thereby influencing the metabolism of drugs that are substrates for both CYP3A and Pgp.
- This finding has implications for understanding drug-drug interactions and optimizing drug therapy.